Neoadjuvant, surgery and adjuvant chemotherapy without radiation for esophageal cancer

Japanese Journal of Clinical Oncology

Volumn 37, Issue 8, 2007, Pages 590-596

  Ardalan, Bach ^c   Spector, Seth A ^a   Livingstone, Alan S ^a   Franceschi, Dido ^a   Mezentsev, Dmitry ^a   Lima, Mayra ^a   Bowen Wells, Carol P ^a   Sparling, Lynne ^a   Avisar, Eli ^a   Sapp, Michelle ^a   Rios, Joyce ^a   Walker, Gail ^a   Ganjei Azar, Parvin ^b  

^a UNIVERSITY OF MIAMI   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF MIAMI   (United States)

Author keywords

Chemo phase I II III; Chemotherapy; Esophageal cancer; GI esophagus med; GI esophagus surg

Indexed keywords

ALBUMIN; CISPLATIN; DIPHENOXYLATE; FLOXURIDINE; FOLINIC ACID; PACLITAXEL;

ABSENCE OF SIDE EFFECTS; ADJUVANT THERAPY; ADULT; AGED; ALOPECIA; ANASTOMOSIS LEAKAGE; ANEMIA; ARTICLE; BLOOD TOXICITY; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; ENDOSCOPIC ECHOGRAPHY; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGUS RESECTION; FATALITY; FATIGUE; FEMALE; FLUID THERAPY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; KARNOFSKY PERFORMANCE STATUS; LEUKOPENIA; LUNG COMPLICATION; LYMPHADENOPATHY; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; OVERALL SURVIVAL; PATIENT SAFETY; PERITONEUM METASTASIS; PHASE 2 CLINICAL TRIAL; POSTOPERATIVE COMPLICATION; SIDE EFFECT; STOMATITIS; SURVIVAL TIME; THROMBOCYTE; TREATMENT REFUSAL; VOMITING;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; CISPLATIN; CLINICAL TRIALS, PHASE II AS TOPIC; COMBINED MODALITY THERAPY; ESOPHAGEAL NEOPLASMS; ESOPHAGECTOMY; FEMALE; FLOXURIDINE; HUMANS; LEUCOVORIN; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; PACLITAXEL;

EID: 44849085489     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hym076     Document Type: Article

References (30)

1. Lightdale C. Esophageal cancer. American College of Gastroenterology. Am J Gastroenterol 1999;94(1):20-9.
2. Peru M. Epidemiology of esophageal cancer, especially adenocarcinoma of the esophagus and esophagogastric junction. Rec Res Cancer Res 2000;155:1-11.
3. De Vita V, Hellman S, Rosenberg S. Cancer: Principals and Practice of Oncology, 6th edn. Philadelphia, PA: Lippincott Williams & Wilkins 2001.
4. Pera M, Cameron A, Trastek VF, Carpenter HA, Zinsmeister AR. Increasing incidence of adenocarcinoma of the esophagus and esophagogastric junction. Gastroenterology 1993;104(2):510-13.
5. Bytzer P, Christensen P, Damkier P, Vinding K, Seersholm N. Adenocarcinoma of the esophagus and Barrett's esophagus: A population-based study. Am J Gatroenterol 1999;94(1):86-91.
6. Devesa SS, Blot WJ, Fraumeni JF Jr. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer 1998;8310:2049-53.
7. Law S, Wong J, Current management of esophageal cancer. J Gastroenterol Surg 2005;9(2):291-310.
8. Farrow D, Vaughan T. Determinants of survival following the diagnosis of esophageal adenocarcinoma (United Slates). Cancer Causes Control 1996;7:322-7.
9. Bonavina L, Soligo D, Quirici N, Bossolasco P, Cesana B, Lembertenghi Deliliers G. A bone marrow-disseminated tumor cells in patients with carcinoma of the esophagus or cardia. Surgery 2001;129(1):15-22.
10. O'Sullivan G, Sheehan D, Clarke A, Stuart R, Kelly J, Kiely MD, et al. Micrometastasis in esophago-gastric cancer: High detection rate in resected rib segments. Gastroenterology 1999 116(3):543-8.
11. Thorban S, Rosenberg R, Busch R, Roder RJ. Epithelial cells in bone marrow of esophageal cancer patients: A significant prognostic factor in multivariate analysis. Br J Cancer 2000;83(1):35-9.
12. Mansi J, Berger U, Easton D, McDonnell T, Redding WH, Gazet JC, et al. Micrometastasis in bone marrow in patients with primary breast cancer: evaluation as an early predictor of bone metastasis. Br Med J 1987;295(6606):1093-6.
13. Braun S, Pantel K. Micrometastatic bone marrow involvement: Detection and prognostic significance. Med Oncol 1999;16:154-65.
14. Cooper JS, Guo MD, Herskovic A, Macdonald JS, Martenson JA Jr, Al-Sarraf M, et al. Chemoradiotherapy of locally advanced esophageal cancer. Long-term follow-up of a prospective randomized trial (RTOG 85-01). JAMA 1999;281:1623-7.
15. Minsky BD, Pajak T, Ginsberg RJ, et al. INT 0123 (RTOG 94-05). A phase III trial of combined modality therapy for esophageal cancer: High dose (64.8 Gy) vs. standard dose (50.4Gy) radiation therapy. J Clin Oncol 2002;20:1167-74.
16. Stewart J, Hoff S, Johnson D, Murray MJ, Butler DR, Elkins CC, et al. Improved survival with neo-adjuvant therapy and resection for adenocarcinoma of the esophagus. Ann Surg 1993;218(4):571-6.
17. Vogel S, Mendenhall W, Sombeck M, Marsh R, Woodward ER. Down staging esophageal cancer after preoperative radiation and chemotherapy. Ann Surg 1995;221(6):685-95.
18. Clark P. Surgical resection with or without preoperative chemotherapy in oesophageal cancer: An updated analysis of a randomized controlled trial conducted by the UK Medical Research Council Upper GI Tract Cancer Group. Proc Am Soc Clin Oncol 2001;20:126 (abstract).
19. Muller JM, Erasmi H, Stelzner M, Zieren U, Pichlmaier H. Surgical therapy of esophageal carcinoma. Br J Surg 1990;77:845-7.
20. Medical Research Council Oesophageal Cancer Working Party. Surgical resection with or without pre-operative chemotherapy in oesophageal cancer: A randomized controlled trial. Lancet 2002;359:1727-33.
21. Bosset JF, Gignoux M, Triboulet JP, Tiret E, Mantion G, Elias D, et al. Chemoradiotherapy followed by surgery compared with surgery alone in squamous cell carcinoma of the esophagus. New Engl J Med 1997;337:161-7.
22. Urba SG, Orringer MB, Turrisi A, Iannettoni M, Forastiere A, Strawderman M. Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. J Clin Oncol 2001;19:305-13.
23. Bonnetain F, Bouche O, Michel P, Mariette C, Conroy T, Pezet D, et al. Randomized phase III trial in locally advanced esophageal cancer: radiochemotherapy followed by surgery versus radiochemotherapy without surgery. Proc Am Soc Clin Oncol 2003;21:130a (abstract 642).
24. Stahl M, Wilke H, Fink U, Stuschke M, Walz MK, Siewert JR, et al. Combined preoperative chemotherapy and radiotherapy in patients with locally advanced esophageal cancer: Interim analysis of a phase II trial. J Clin Oncol 1996;14:829-37.
25. Walsh T, Noonan N, Hollywood D, Kelly A, Keeling N, Hennessy TP. A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. New Engl J Med 1996;335:462-7.
26. American Joint Committee on Cancer. AJCC Cancer Staging Manual, 6th edn. New York: Springer 2002.
27. Karnofsky DA, Burchenal JH. The clinical evaluation of chemotherapeutic agents in cancer. MacLeod CM, editor. Evaluation of Chemotherapeutic Agents. New York: Columbia University Press 1949;45-9.
28. Cunningham D, Allum W, Weeden S. Perioperative chemotherapy in operable gastric and lower oesophageal cancer: A randomized, controlled trial of the UK NCRI Upper GI Clinical Studies Group (the MAGIC trial, ISRCTN 93793971). Eur J Cancer 2003;5(Suppl 1):18 (abstract 45).
29. Kelsen DP, Ginsberg R, Pajak TF, Sheahan DG, Gunderson L, Mortimer J, et al. Chemotherapy followed by surgery alone for localized esophageal cancer. New Engl J Med 1998;339(27):1979-84.
30. Ajani JA. Docetaxel for gastric and esophageal carcinomas. In: Oncology, Williston Park, 16 June 2002, Vol 6, Suppl 6;89-96.